Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Nature Medicine|October 2, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trialNizar J Bahlis, Caitlin L Costello, Noopur S Raje, et al.
Cancer|April 17, 2024
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myelomaAttaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
Blood|May 27, 2008
Cyproheptadine displays preclinical activity in myeloma and leukemiaXinliang Mao, Sheng-ben Liang, Rose Hurren, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.
Blood|November 5, 2025
PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolismCecilia Bonolo De Campos, Ruijuan He, Tessa Josephine Pelino, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Cancer|August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trialAjay K Nooka, Adam D Cohen, Hans C Lee, et al.
Pageof 11